Valneva Reports Wider 2025 Loss Despite Revenue Growth

Valneva Posts Widened Net Loss for 2025 Despite Modest Revenue Increase

French vaccine manufacturer Valneva reported a significant widening of its net loss to €115.20 million for the full year 2025, a sharp decline compared to the previous year. The increased loss is primarily attributed to the absence of a one-off gain that had positively impacted 2024 results.

Financial Performance Breakdown

Despite the loss, the company's total revenue saw a modest increase, driven by higher sales of its proprietary vaccines for Japanese encephalitis and chikungunya. This growth helped offset a decrease in third-party product sales. However, gross margins were negatively affected by increased manufacturing costs, batch failures, and inventory write-offs. The company reported an adjusted EBITDA of negative €59.40 million for the year.

Operational Challenges and Future Outlook

Valneva's research and development expenses rose due to its Shigella vaccine program and post-marketing obligations. Looking ahead to 2026, the company reiterated its revenue guidance, projecting total revenues between €155 million and €170 million. Valneva also anticipates a reduction in operating cash burn and expects to release key clinical trial readouts during the year.

Summary and Key Takeaways

Valneva faces a challenging period with widening losses and margin pressures but maintains a positive revenue outlook for 2026. Investors will be closely watching the company's ability to manage costs, reduce cash burn, and deliver on its upcoming clinical trial milestones.

FAQ

Q: Why did Valneva's net loss increase in 2025?
A: The wider loss was mainly due to the absence of a one-off gain that benefited 2024 results, alongside higher manufacturing costs and increased R&D spending.

Q: What is Valneva's revenue outlook for 2026?
A: Valneva projects total revenues between €155 million and €170 million for 2026, with product sales expected to range from €145 million to €160 million.

Source: Investing.com